Virax Biolabs Group (Virax Biolabs Group) EBIT per Share : $-18.89 (TTM As of Sep. 2023)

View and export this data going back to 2022. Start your Free Trial

What is Virax Biolabs Group EBIT per Share?

Virax Biolabs Group's EBIT per Share for the six months ended in Sep. 2023 was $-16.32. Its EBIT per Share for the trailing twelve months (TTM) ended in Sep. 2023 was $-18.89.

During the past 3 years, the average EBIT per Share Growth Rate was -67.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for Virax Biolabs Group's EBIT per Share or its related term are showing as below:

VRAX' s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -67.6 Med: -67.6 Max: -67.6
Current: -67.6

During the past 4 years, the highest 3-Year average EBIT per Share Growth Rate of Virax Biolabs Group was -67.60% per year. The lowest was -67.60% per year. And the median was -67.60% per year.

VRAX's 3-Year EBIT Growth Rate is ranked worse than
93.39% of 1301 companies
in the Biotechnology industry
Industry Median: 3.4 vs VRAX: -67.60

Virax Biolabs Group's EBIT for the six months ended in Sep. 2023 was $-2.90 Mil.

Virax Biolabs Group EBIT per Share Historical Data

The historical data trend for Virax Biolabs Group's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Virax Biolabs Group EBIT per Share Chart

Virax Biolabs Group Annual Data

Trend

Mar20

Mar21

Mar22

Mar23

EBIT per Share

-0.57

-1.53

-2.56

Virax Biolabs Group Semi-Annual Data
	Mar20	Sep20	Mar21	Sep21	Mar22	Sep22	Mar23	Sep23
EBIT per Share	Get a 7-Day Free Trial			-0.49	-1.03	-3.70	-2.57	-16.32

Virax Biolabs Group EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

Virax Biolabs Group's EBIT per Share for the fiscal year that ended in Mar. 2023 is calculated as

	EBIT per Share		(A: Mar. 2023 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-5.442	/	2.126
=	-2.56

Virax Biolabs Group's EBIT per Share for the quarter that ended in Sep. 2023 is calculated as

	EBIT per Share		(Q: Sep. 2023 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-2.904	/	0.178
=	-16.31

EBIT per Share for the trailing twelve months (TTM) ended in Sep. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was $-18.89

Virax Biolabs Group (NAS:VRAX) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

Virax Biolabs Group EBIT per Share Related Terms

Thank you for viewing the detailed overview of Virax Biolabs Group's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Virax Biolabs Group (Virax Biolabs Group) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Virax Biolabs Group Ltd (NAS:VRAX) » Definitions » EBIT per Share

Comparable Companies

Traded in Other Exchanges

N/A

Address

20 North Audley Street, London, GBR, W1K 6LX

Website

https://www.viraxbiolabs.com

Virax Biolabs Group Ltd is a innovative biotechnology company focused on the prevention, detection, diagnosis and risk management of viral diseases that also engages in distribution of diagnostics test kits of various viral threats. It is developing a proprietary T-Cell Test technology with the intention of providing an immunology profiling platform that assesses each individual's immune risk profile against major global viral threats. T-Cell testing is particularly effective in the diagnosis and therapeutics of COVID-19 as well as other threats including Hepatitis B, Malaria, Herpes and Human Papillomavirus.